Status:
COMPLETED
Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma
Lead Sponsor:
Alexandria University
Conditions:
Glaucoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Glaucoma encompasses a collective group of optic neuropathies characterized by progressive degeneration of retinal ganglion cells and their axons, resulting in cupping, a distinctive appearance of the...
Detailed Description
Saflutan® is the first preservative-free prostaglandin analog introduced to the Egyptian market. It contains the PG analog tafluprost. Better tolerability, higher adherence to treatment and improvemen...
Eligibility Criteria
Inclusion
- Adult males and females, newly diagnosed with glaucoma, naïve to glaucoma medications and surgery, able to read, comprehend, and complete the Ocular Surface Disease Index (OSDI) questionnaire, and able to provide informed consent form.
Exclusion
- Unable to provide informed consent form
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04455126
Start Date
April 1 2018
End Date
June 1 2020
Last Update
July 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria Faculty of Medicine
Alexandria, Egypt